S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:ETNB

89bio (ETNB) Stock Forecast, Price & News

$20.30
+0.13 (+0.64%)
(As of 06/9/2023 ET)
Compare
Today's Range
$19.97
$20.49
50-Day Range
$14.15
$20.45
52-Week Range
$2.91
$20.85
Volume
693,763 shs
Average Volume
1.12 million shs
Market Capitalization
$1.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

89bio MarketRank™ Forecast

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
67.5% Upside
$34.00 Price Target
Short Interest
Healthy
9.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of 89bio in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$41.02 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.92) to ($2.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

421st out of 987 stocks

Pharmaceutical Preparations Industry

197th out of 482 stocks


ETNB stock logo

About 89bio (NASDAQ:ETNB) Stock

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

ETNB Stock News Headlines

"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
SVB Securities Keeps Their Buy Rating on 89bio (ETNB)
89bio (NASDAQ: ETNB)
89bio (NASDAQ:ETNB) Stock Price Up 3.3%
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
89bio (ETNB) Investor Presentation - Slideshow
89bio (NASDAQ:ETNB) Reaches New 12-Month High at $18.88
89bio, Inc. (NASDAQ:ETNB) Insider Sells $247,799.13 in Stock
89bio (NASDAQ:ETNB) Stock Price Down 6.1%
Brokerages Set 89bio, Inc. (NASDAQ:ETNB) Price Target at $32.22
Short Interest in 89bio, Inc. (NASDAQ:ETNB) Increases By 44.0%
See More Headlines

ETNB Price History

ETNB Company Calendar

Last Earnings
5/04/2023
Today
6/10/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETNB
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+67.5%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-102,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.00 per share

Miscellaneous

Free Float
69,662,000
Market Cap
$1.48 billion
Optionable
Not Optionable
Beta
0.76

Key Executives

  • Mr. Rohan PalekarMr. Rohan Palekar (Age 56)
    CEO & Director
    Comp: $829.41k
  • Mr. Quoc Le-Nguyen (Age 54)
    Chief Technical Operations Officer & Head of Quality
    Comp: $571.12k
  • Dr. Harry Mansbach M.D. (Age 57)
    Chief Medical Officer
    Comp: $603.22k
  • Mr. Ryan Stephen Martins (Age 44)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan (Age 56)
    Sr. VP of Fin. & Principal Accounting Officer
  • Ms. Melissa Abel
    Sr. VP of Commercial Strategy & Communications
  • Ms. Amanda Hill
    VP of People & Culture
  • Ms. Yun Bai
    VP & Head of CMC
  • Mr. Paul Shin
    Sr. VP of R&D Operations













ETNB Stock - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price forecast for 2023?

7 brokerages have issued 12-month price objectives for 89bio's shares. Their ETNB share price forecasts range from $24.00 to $50.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 67.5% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2023?

89bio's stock was trading at $12.73 at the beginning of 2023. Since then, ETNB shares have increased by 59.5% and is now trading at $20.30.
View the best growth stocks for 2023 here
.

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ETNB earnings forecast
.

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.02.

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

(ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What is 89bio's stock symbol?

89bio trades on the NASDAQ under the ticker symbol "ETNB."

Who are 89bio's major shareholders?

89bio's stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (4.21%), Federated Hermes Inc. (3.49%), Suvretta Capital Management LLC (3.03%), Boxer Capital LLC (2.88%), BVF Inc. IL (2.53%) and BlackRock Inc. (1.71%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Longitude Capital Partners Iii, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends
.

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 89bio's stock price today?

One share of ETNB stock can currently be purchased for approximately $20.30.

How much money does 89bio make?

89bio (NASDAQ:ETNB) has a market capitalization of $1.48 billion. The company earns $-102,030,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

How can I contact 89bio?

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com.

This page (NASDAQ:ETNB) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -